All In Biotech

Drug Trial Radar · NCT02565576

Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia Gravis

A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Preliminarily Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of CFZ533 in Patients With Moderate to Severe Myasthenia Gravis

Last checked: Nov 19, 2026Latest source record: Jan 5, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

44

Actual

Start

Sep 29, 2015

Primary completion

Jul 31, 2017

Study completion Dec 19, 2017

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Oct 1, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate safety, tolerability, pharmacokinetics/pharmacodynamics and efficacy of CFZ533 as an add-on therapy to standard of care in patients with moderate to severe myasthenia gravis (MG).

Conditions

  • Myasthenia Gravis, Generalized

Interventions

  • PlaceboDrug

  • CFZ533Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change From Baseline in the Quantitative Myastenia Gravis (QMG) Score at Week 25. Posterior Median Was Used as Measure Type.Time frame: week 25

Locations

15 sites in 5 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Montreal, Quebec, Canada

  • Novartis Investigative Site

    Québec, Quebec, Canada

  • Novartis Investigative Site

    Aarhus, Denmark

  • Novartis Investigative Site

    Copenhagen, Denmark

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Halle/S, Germany

  • Novartis Investigative Site

    München, Germany

  • Novartis Investigative Site

    Barnaul, Russia

  • Novartis Investigative Site

    Kazan', Russia

  • Novartis Investigative Site

    Novosibirsk, Russia

  • Novartis Investigative Site

    S-Petersburg, Russia

  • Novartis Investigative Site

    Samara, Samara Oblast, Russia

  • Novartis Investigative Site

    Taipei, Taiwan

  • Novartis Investigative Site

    Taipei, Taiwan

  • Novartis Investigative Site

    Tainan, Taiwan ROC, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.